Zobrazeno 1 - 10 of 34 pro vyhledávání: '"Gilles Tapolsky"'
1
BXQ-350 may alleviate symptoms of chemotherapy- induced peripheral neuropathy via modulation of S1P
Autor: Robert Wesolowski, Anne M. Noonan, Richard Charles Curry, John Charles Morris, Carolyn Muller, Vinay K. Puduvalli, Olivier Rixe, John L. Villano, Trisha Michel Wise-Draper, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v: Journal of Clinical Oncology. 41:93-93
93 Background: Chemotherapy Induced Peripheral Neuropathy (CIPN) is a debilitating side effect associated with many chemotherapeutic agents. It significantly impacts quality of life during treatment, causes lasting neuropathy, and may also shorten th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b600926c79eca1d6fda41b258b751e73
https://doi.org/10.1200/jco.2023.41.4_suppl.93
Zobrazit plný text záznamu
2
BXQ-350: Modulating ceramide and sphingosine-1-phosphate for antitumor activity in patients with advanced CRC
Autor: Olivier Rixe, Richard Charles Curry, John Charles Morris, Carolyn Muller, Anne M. Noonan, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Robert Wesolowski, Emrullah Yilmaz, Gilles Tapolsky, Ray Takigiku
Publikováno v: Journal of Clinical Oncology. 41:154-154
154 Background: Sphingolipids are a class of bioactive signaling molecules implicated in multiple cellular processes and molecular pathways. Many publications have demonstrated that ceramides are proapoptotic, synergize with cancer treatments, and mi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86ec219e4d804e7900198a33328e0221
https://doi.org/10.1200/jco.2023.41.4_suppl.154
Zobrazit plný text záznamu
3
Bedside to benchtop translational development: Targeting the S1P/ceramide axis may alleviate symptoms of chemical induced peripheral neuropathy
Autor: Ray Takigiku, Robert Wesolowski, Olivier Rixe, John Charles Morris, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Richard Charles Curry, Vinay K. Puduvalli, Trisha Michel Wise-Draper, Darren Wolfe, Gilles Tapolsky
Publikováno v: Journal of Clinical Oncology. 40:e15045-e15045
e15045 Background: Chemical Induced Peripheral Neuropathy (CIPN) is a debilitating and serious side-effect associated with many chemotherapeutic treatments. Often, CIPN is a dose-limiting toxicity, and its effects can be long-lasting in some patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78164a56b513a0cf7268aec4fbae82a6
https://doi.org/10.1200/jco.2022.40.16_suppl.e15045
Zobrazit plný text záznamu
4
S1P/ceramides and cytokines as potential biomarkers of response following administration of bxq-350
Autor: Gilles Tapolsky, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, Anne M. Noonan, John L. Villano, Richard Charles Curry, Carolyn Muller, Trisha Michel Wise-Draper, Vinay K. Puduvalli, Ray Takigiku
Publikováno v: Journal of Clinical Oncology. 40:e15007-e15007
e15007 Background: BXQ-350 was investigated in a Phase 1 dose-escalation safety study of all-comer cancer patients with advanced solid malignancies, including high grade gliomas ( NCT02859857 ) (safety/efficacy results reported in a separate abstract
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::91f78013f499e560771ecb57636a7b08
https://doi.org/10.1200/jco.2022.40.16_suppl.e15007
Zobrazit plný text záznamu
5
A phase 1, safety and dose escalation study of BXQ-350, a nanovesicle formulation of saposin c, a modulator of sphingolipid metabolism, in patients with advanced solid malignancies
Autor: Richard Charles Curry, Olivier Rixe, John Charles Morris, Robert Wesolowski, Emrullah Yilmaz, John L. Villano, Carolyn Muller, Trisha Michel Wise-Draper, Anne M. Noonan, Vinay K. Puduvalli, Gilles Tapolsky, Ray Takigiku
Publikováno v: Journal of Clinical Oncology. 40:e15059-e15059
e15059 Background: Bexion recently completed an all-comer Phase 1 clinical study of BXQ-350 in patients with advanced solid tumors including high grade gliomas to evaluate the safety profile and to determine the maximum tolerated- or biologically eff
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ca2a51cc49a485b693243d28b85048d
https://doi.org/10.1200/jco.2022.40.16_suppl.e15059
Zobrazit plný text záznamu
6
DIPG-30. A Phase 1, Safety and Dose Escalation Study of BXQ-350 in Combination with Radiation in Pediatric Patients with Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Autor: Kathleen McCarthy O'Toole Dorris, Maryam Fouladi, Trent Hummel, Ray Takigiku, Gilles Tapolsky, Richard Curry III
Publikováno v: Neuro-Oncology. 24:i25-i25
The significance of sphingolipid metabolism in brain cancers has been demonstrated and enzymes involved in sphingolipid metabolism are being investigated as novel therapeutic targets for adult and pediatric brain cancers. Saposin C is a human protein
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce34bc057476d910187be1868a986ad0
https://doi.org/10.1093/neuonc/noac079.087
Zobrazit plný text záznamu
8
Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Autor: Yaxian Wang, Wen Xuyang, Sucheta Telang, Julie Staub, Ling Jin, Debarshi Roy, Dzeja Petras, Gilles Tapolsky, Jeremey Chien, Sayantani Sarkar Bhattacharya, Ashwani Khurana, Deok-Beom Jung, Viji Shridhar, Jason Chesney, Eleftheria Kalogera, Song Zhang, Susmita Mondal
Publikováno v: International Journal of Cancer. 144:178-189
Metabolic alterations are increasingly recognized as important novel anti-cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95e4b9177530409e64fe6e4dbb873ad3
https://doi.org/10.1002/ijc.31868
Zobrazit plný text záznamu
9
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Autor: John O. Trent, Sucheta Telang, Rebecca Redman, Julie O'Neal, Jason Chesney, Brian F. Clem, Amy L. Clem, Alden C. Klarer, Daniel Alan Kerr, Yoannis Imbert-Fernandez, Donald M. Miller, Gilles Tapolsky
Publikováno v: Molecular Cancer Therapeutics. 12:1461-1470
In human cancers, loss of PTEN, stabilization of hypoxia inducible factor-1α, and activation of Ras and AKT converge to increase the activity of a key regulator of glycolysis, 6-phosphofructo-2-kinase (PFKFB3). This enzyme synthesizes fructose 2,6-b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3760e55f5c9a3d7e4289ce1bc3b391ad
https://doi.org/10.1158/1535-7163.mct-13-0097
Zobrazit plný text záznamu
10
Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients
Autor: Siqing Fu, Jason Chesney, Paula R. Pohlmann, Rebecca Redman, Kavitha Yaddanapudi, Jaspreet Singh Grewal, Michael R. Kurman, Gilles Tapolsky, Devalingam Mahalingam, Sucheta Telang
Publikováno v: Cancer Research. 76:B90-B90
Background: 6-phosphofructo-2-kinase (PFKFB3) is an enzyme that controls the intracellular concentration of fructose-2,6-bisphosphate which is an allosteric activator of 6-phosphofructo-1-kinase (PFK-1), a key enzyme of glycolysis. PFK-1 is tightly c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f476d624a3746b8eb8461f46e6da277
https://doi.org/10.1158/1538-7445.panca16-b90
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje